← All trials
NCT06419374
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 24, 2024
- Primary completion
- Jun 30, 2028
- Completion date
- Aug 31, 2031
- First posted
- May 17, 2024
- Last posted
- Nov 11, 2024
- Enrollment
- 762
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- 89bio Ltd.Lead sponsor
- 89bio Ltd.Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.